Latest News about RHHBY
Recent news which mentions RHHBY
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
August 16, 2024
From Benzinga
From Benzinga
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
August 15, 2024
From Motley Fool
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
August 13, 2024
From Benzinga
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
August 08, 2024
From Benzinga
Here's Why Eli Lilly Stock Dropped 12% Last Month
August 08, 2024
From Motley Fool
Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions
August 07, 2024
From Benzinga
From Benzinga
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
August 02, 2024
From Motley Fool
From Motley Fool
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
July 24, 2024
From Benzinga
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
July 23, 2024
From Motley Fool
From Benzinga
Tickers
RHHBY
From Motley Fool
From Motley Fool
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
July 18, 2024
From Benzinga
From Benzinga
From Motley Fool
From Benzinga
From Benzinga
Roche Highlights Encouraging Data From Newly-Acquired Second Weight Loss Drug Candidate In Early-Stage Study
July 17, 2024
From Benzinga
3 Small-Cap Stocks With Explosive 2X Growth Potential
July 08, 2024
From InvestorPlace
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
July 05, 2024
From Benzinga
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
June 27, 2024
From Benzinga
From Benzinga
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
June 21, 2024
From Benzinga
From InvestorPlace
From Benzinga
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
June 07, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.